Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis.
Angiotensin-converting enzyme (ACE) inhibitors diminish proteinuria and the progression to renal failure in several experimental models of renal injury. Endothelin-1 (ET-1) possesses potent biological actions on renal vessels and has been considered as a potential mediator of renal damage. Because angiotensin II (Ang II) induces ET-1 synthesis in endothelial and mesangial cells, we hypothesized that some of the beneficial effects of the ACE inhibitors could result from the blockade of ET-1 synthesis. In a normotensive model of immune-complex nephritis, in which there exists an increase in renal ACE activity, the effect of the ACE inhibitor quinapril on preproET-1 and ETA receptor mRNA expression, as well as on ET-1 protein levels, was examined in this study. In relation to controls, nephritic rats showed an increase in preproET-1 and ETA receptor gene expression in renal cortex and medulla, coinciding with the maximal renal ACE activity. PreproET-1 mRNA (in situ hybridization) and ET-1 protein (immunohistochemistry) were localized in glomerular capillary walls, mesangial and glomerular epithelial cells, as well as in the brush border of some proximal tubules, and in small vessels. In nephritic rats, there was an increase in preproET-1 mRNA levels and ET-1 protein in all of these areas, without modification of their distribution. The administration of the ACE inhibitor quinapril decreased proteinuria and morphological lesions, preproET-1 gene transcription, and ET-1 protein levels, as well as the ETA receptor mRNA. The results from this study show that in a normotensive model of immune-complex nephritis, there was an overexpression of ET-1 in several structures of the kidney that was downregulated by quinapril administration. The beneficial effect of ACE inhibitors could be a result of the modulation of local production of Ang II and ET-1.
Ruiz-Ortega
M
M
Renal Unit, Fundación Jiménez Díaz, Universidad Autónoma, Madrid, Spain.
Gómez-Garre
D
D
Liu
X H
XH
Blanco
J
J
Largo
R
R
Egido
J
J
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D000936:Antigen-Antibody Complex / Q000276:immunology*; D001794:Blood Pressure; D019332:Endothelin-1 / Q000378:metabolism*; D016232:Endothelins / Q000235:genetics; D005260:Female; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D007546:Isoquinolines / Q000494:pharmacology*; D007668:Kidney / Q000378:metabolism* / Q000473:pathology; D009393:Nephritis / Q000276:immunology* / Q000378:metabolism* / Q000503:physiopathology; D011498:Protein Precursors / Q000235:genetics; D000077583:Quinapril; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D017466:Receptors, Endothelin / Q000235:genetics; D012016:Reference Values; D013194:Staining and Labeling; D044005:Tetrahydroisoquinolines
D000806:Angiotensin-Converting Enzyme Inhibitors; D000936:Antigen-Antibody Complex; D019332:Endothelin-1; D016232:Endothelins; D007546:Isoquinolines; D011498:Protein Precursors; D012333:RNA, Messenger; D017466:Receptors, Endothelin; D044005:Tetrahydroisoquinolines; D000077583:Quinapril